Bicara Therapeutics Inc 8-K, filed Jun 10, 2026
Bicara Therapeutics Inc. (BCAX)
8-K
2026-06-10
For: 2026-06-09
View Original
Added on
June 10, 2026
About this 8-K
Bicara Therapeutics Inc filed this 8-K on June 10, 2026, reporting on events of June 9, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 9, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 9, 2026, Bicara Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2026. Of the 65,600,370 shares of the Company’s common stock outstanding as of the record date, 55,924,987 shares, or approximately 85.25%, were present or represented at the Annual Meeting. Set forth below are the final results of the matters submitted for a vote of the stockholders at the Annual Meeting.
Proposal 1: Election of Directors
The Company’s stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows:
Director | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
Christopher Bowden, M.D. | 48,558,710 | 5,145,418 | 2,220,859 | |||||||||||||||||
Carolyn Ng, Ph.D. | 47,431,269 | 6,272,859 | 2,220,859 | |||||||||||||||||
Proposal 2: Ratification of KPMG LLP
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:
Votes For | Votes Against | Votes Abstaining | ||||||||||||||||||
Ratification of appointment of KPMG LLP | 55,914,602 | 8,815 | 1,570 | |||||||||||||||||
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bicara Therapeutics Inc. | |||||||||||
Date: June 10, 2026 | By: | /s/ Claire Mazumdar | |||||||||
Name: | Claire Mazumdar, Ph.D. | ||||||||||
Title: | Chief Executive Officer | ||||||||||